Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with pancreatic, duodenal, or small intestine fistula~* Patient with simple, externalised fistula~* Patient with fistula for which a medical conservative treatment is considered~* Patient with:~* for pancreatic fistulae: a mean drainage volume more than or equal to 100 ml/24h over 48 hours or more than or equal to 50 ml / 24h over 3 days and a concentration of amylase in the drainage fluid 3 times higher than in the serum over at least 2 or 3 consecutive days respectively,~* for duodenal and small intestine fistulae: a mean drainage volume more than or equal to 100ml/24h over 2 days~Exclusion Criteria:~* Patient expected to require a surgical treatment of the fistula during the study~* Patient having uncontrolled intra-abdominal sepsis; Crohn's disease; radiotherapy lesions of the small bowel; a mesenteric vascular insufficiency; a fistula localised in cancer-infiltrated areas; a distal obstruction; an exposed fistula of the small intestine; or intra-abdominal foreign bodies.~* Patient receiving long-term corticotherapy~* Patient having received any somatostatin analogue as curative treatment of the fistula or any PRF somatostatin analogue within the previous month.~* Patient having previously undergone a transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Drug: Lanreotide 30 mg microparticle formulation~One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of lanreotide 30 mg microparticle formulation every 10 days): according to the patient's treatment response at 72h~For non-responders patients lanreotide will be stopped.
- 2 (Type: PLACEBO_COMPARATOR): One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of placebo every 10 days): according to the patient's treatment response at 72h.~Non-responder patients having received placebo on the first injection should receive an open-labelled lanreotide treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).